Pulsed vs standard radiation for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new way of giving radiation therapy (pulsed) compared to standard radiation for people with a specific type of glioblastoma (IDH wildtype, MGMT unmethylated). The goal is to see if the pulsed approach helps with thinking and memory while still treating the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of brain tumor called IDH wildtype, MGMT unmethylated glioblastoma that is newly diagnosed.
- You must have had surgery to remove as much of the tumor as possible (a biopsy alone is not enough).
- You must be able to speak English or French Canadian for memory and thinking tests.
- You must be well enough to do daily activities (Karnofsky score of 70 or more).
- You must not have had prior radiation to the brain or other cancer treatments for this tumor besides surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.